REBEL MEDICINE INC
Novel long-acting injectable local anesthetic drug using oleogel-based delivery system for sustained bupivacaine release
- Sector
- Medtech
- Headquarters
- Salt Lake City, UT
- Founded
- 2020
- Latest Form D
- $6.1M, Feb 2025
- Total capital
- $8.1M
- Federal grants
- $2.1M
- 4 awards · 2021–2024
- Rank in peer group#21 of 41
- Private capital raised
- $6.1M
- 1 Form D · last Feb 2025
- 20 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 5 pending · first 2024
- Rank in peer group#13 of 41
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$6.1M
- Federal grantHealth and Human S · Phase I · Extending duration of an injectable long-acting local anesthetic formulation using novel salts$296K
- Federal grantNSF · Phase II · SBIR Phase II:Novel, injectable, long-acting, local anesthetic for postoperative pain management$1.5M
- Federal grantHealth and Human S · Phase I · Development of a novel sustained release local anesthetic wound dressing for partial-thickness dermal injuries$7K
- Federal grantHealth and Human S · Phase I · Development of a novel sustained release local anesthetic wound dressing for partial-thickness dermal injuries$257K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
41months
from REBEL MEDICINE INC’s first federal award to its first private round.
- First federal award · Sep 2021
- Health and Human S · $257K
- First Form D · Feb 2025
- $6.1M · 1st Form D
- Awards before first raise
- 4 awards
An association in public records, not a cause or a prediction.
Standing among 41 peers
Line = medianMedtech · Molecule
- Federal grants#21 · top 51%
- Granted patents#13 · top 32%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Brett DavisResearcherExecutive Officer, DirectorLinked by $2.6M in grants as PI
- Caleb LadeExecutive Officer, DirectorNamed in SEC Form D filings
- John PoyhonenDirectorNamed in SEC Form D filings
- Kevin PasseyDirectorNamed in SEC Form D filings
- Mai NguyenDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 6- PendingPharmaceutical Compositions For Treating PainUSPTOApplication 18422543
- GrantedPharmaceutical Compositions For Treating PainUSPTOUS 11,918,572
- PendingPharmaceutical Oil-in-water Emulsion For Treating PainUSPTOApplication PCTUS2025022979
Show all 6 patent records
- Pharmaceutical Compositions For Treating PainMay 16, 2024 · Application 18422543Pending
- Pharmaceutical Compositions For Treating PainMar 5, 2024 · US 11,918,572Granted
- Pharmaceutical Oil-in-water Emulsion For Treating PainApplication PCTUS2025022979Pending
- Pharmaceutical CompositionsApplication PCTUS2024037678Pending
- Extended-release Composite Wound DressingApplication PCTUS2023067402Pending
- Pharmaceutical Compositions For Treating PainApplication PCTUS2023061464Pending
Related companies, and why
- 109 Therapeutics, Inc.Shares a founder: BRETT DAVIS
- SolvingDynamics, Inc.Similar federal contract value in Medtech · null in contracts
- ECLIPSE ENTEROGENESIS, INC.Similar federal contract value in Medtech · null in contracts
- VenoStent, Inc.Similar federal contract value in Medtech · null in contracts
- ISONO HEALTH, INC.Similar federal contract value in Medtech · null in contracts
- Sonavex, Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .